Skip to content

A PHASE 3B, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF SUBCUTANEOUS LY2127399 IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) (ILLUMINATE-X)

A PHASE 3B, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF SUBCUTANEOUS LY2127399 IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) (ILLUMINATE-X)

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
REPEC
Registry ID
PER-068-12
Enrollment
26
Registered
2013-01-14
Start date
Unknown
Completion date
Unknown
Last updated
2023-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

WEEK 52 OF STUDY BCDS AND STUDY BCDT CORRESPOND TO WEEK 0 IN STUDY BCDX. THE WEEK 52 VISIT IN STUDY BCDS OR STUDY BCDT SHOULD OCCUR ON THE SAME CALENDAR DAY (OR WITHIN 3 DAYS AFTER) AS THE FIRST VISIT

Sponsors

ELI LILLY AND COMPANY,
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: [1] HAVE COMPLETED 52 WEEKS OF TREATMENT IN STUDY BCDS OR STUDY BCDT. [2A] FOR FEMALE PATIENTS OF CHILDBEARING POTENTIAL, MUST TEST NEGATIVE FOR PREGNANCY AT THE TIME OF ENROLLMENT AND AGREE TO USE A RELIABLE METHOD OF BIRTH CONTROL OR REMAIN ABSTINENT DURING THE STUDY OR FOR AT LEAST 8 WEEKS FOLLOWING THE LAST DOSE OF STUDY DRUG, WHICHEVER IS LONGER, OR [2B] FOR FEMALE PATIENTS OF NON-CHILDBEARING POTENTIAL, DEFINED AS: . WOMEN WHO HAVE HAD SURGICAL STERILIZATION (HYSTERECTOMY OR BILATERAL OOPHORECTOMY OR TUBAL LIGATION) . WOMEN &#8805; 60 YEARS OF AGE . WOMEN &#8805; 40 AND < 60 YEARS OF AGE WHO HAVE HAD A CESSATION OF MENSES FOR AT LEAST 12 MONTHS AND A FOLLICLE-STIMULATING HORMONE (FSH) TEST CONFIRMING NON-CHILDBEARING POTENTIAL (FSH &#8805; 40 MIU/ML). [3] HAVE GIVEN WRITTEN INFORMED CONSENT APPROVED BY LILLY OR ITS DESIGNEE AND THE INVESTIGATIONAL REVIEW BOARD/ETHICAL REVIEW BOARD (IRB/ERB) GOVERNING THE SITE.

Exclusion criteria

Exclusion criteria: [4] PRESENCE OF SIGNIFICANT UNCONTROLLED CEREBROCARDIOVASCULAR (FOR EXAMPLE: MYOCARDIAL INFARCTION [MI], UNSTABLE ANGINA, UNSTABLE ARTERIAL HYPERTENSION, SEVERE HEART FAILURE, OR CEREBROVASCULAR ACCIDENT), RESPIRATORY, HEPATIC, RENAL, GASTROINTESTINAL, ENDOCRINE, HEMATOLOGIC OR NEUROPSYCHIATRIC DISORDERS, OR ABNORMAL LABORATORY VALUES AT BASELINE THAT IN THE OPINION OF THE INVESTIGATOR POSE AN UNACCEPTABLE RISK TO THE PATIENT IF STUDY DRUG WOULD BE ADMINISTERED. [5] HAVE ANY OTHER CONDITION THAT RENDERS THE PATIENT UNABLE TO UNDERSTAND THE NATURE, SCOPE, AND POSSIBLE CONSEQUENCES OF THE STUDY OR PRECLUDES THE PATIENT FROM FOLLOWING AND COMPLETING THE PROTOCOL, IN THE OPINION OF THE INVESTIGATOR. [6] ARE UNWILLING OR UNABLE TO COMPLY WITH STUDY PROCEDURES. [7] ARE INVESTIGATOR SITE PERSONNEL DIRECTLY AFFILIATED WITH THIS STUDY AND/OR THEIR IMMEDIATE FAMILIES. IMMEDIATE FAMILY IS DEFINED AS A SPOUSE, PARENT, CHILD, OR SIBLING, WHETHER BIOLOGICAL OR LEGALLY ADOPTED. [8] ARE LILLY EMPLOYEES OR REPRESENTATIVES OF A THIRD PARTY ORGANIZATION (TPO) INVOLVED IN THE STUDY WHO REQUIRE EXCLUSION OF THEIR EMPLOYEES.

Countries

United States

Contacts

Public ContactYngrid Saldarriaga

PAREXEL INTERNATIONAL (PERU) S.A.

yngrid.saldarriaga@parexel.com4176447

Outcome results

None listed

Source: REPEC (via WHO ICTRP)